Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome.
Probiotic bacteria exhibit a variety of properties, which are unique to a particular strain. Lactobacillus acidophilus-SDC 2012, 2013 are new strains isolated from Korean infants' feces. The potential utility of Lactobacillus acidophilus-SDC 2012, 2013 in irritable bowel syndrome (IBS) was studied. Forty IBS patients were randomized into a placebo (n = 20) and probiotics group (n = 20). Four weeks of treatment with L. acidophilus-SDC 2012, 2013 was associated with a reduced score for abdominal pain or discomfort compared to the baseline (P = 0.011). The percent reduction in abdominal pain or discomfort exceeded the placebo scores by more than 20% (23.8 and 0.2% for probiotics and placebo, respectively, P = 0.003). There was a significant difference in the proportion of responders between the probiotics and placebo groups (P = 0.011). There was no drop out or adverse events for either group during the study period. Lactobacillus acidophilus-SDC 2012, 2013 appeared to have a beneficial effect in patients with IBS. Further studies are warranted.
Sinn
Dong Hyun
DH
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Song
Ji Hyun
JH
Kim
Hoi Jin
HJ
Lee
Jun Haeng
JH
Son
Hee Jung
HJ
Chang
Dong Kyung
DK
Kim
Young-Ho
YH
Kim
Jae J
JJ
Rhee
Jong Chul
JC
Rhee
Poong-Lyul
PL
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000208:ethnology / Q000628:therapy*; D007723:Korea; D007779:Lactobacillus acidophilus / Q000145:classification / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D019936:Probiotics / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome